孟鲁司特联合布地奈德治疗小儿哮喘临床疗效及复发率分析
|
摘要
目的探讨小儿哮喘采用孟鲁司特联合布地奈德治疗的临床效果及对复发率发生情况的影响。方法纳入该院2017年4月—2018年4月收治的90例哮喘患儿,按照随机数字表法均分为两组,各45例,对照组给予单纯布地奈德治疗,观察组在对照组治疗基础上加以孟鲁司特治疗,比较两组临床疗效,治疗前后肺功能指标、3个月内复发率。结果观察组治疗显效率和总有效率分别为71.11%、95.56%,显著高于对照组的53.33%、80.00%,差异有统计学意义(χ~2=8.580、12.121,P<0.05);观察组治疗后的FEV1、、PEF、FVC水平分别为(2.26±0.22)L、(3.42±0.63)L/s、(3.96±0.40)L,均显著高于对照组,差异有统计学意义(t=10.146、4.589、10.213,P<0.05);观察组复发率为2.22%,显著低于对照组的11.11%,差异有统计学意义(χ~2=4.234,P<0.05)。结论对于哮喘患儿,给予孟鲁司特与布地奈德联合效果确切,可显著改善患儿肺功能,降低复发率。
Objective To study the clinical curative effect and recurrent rate of montelukast and budesonide in treatment of children with asthma. Methods 90 cases of asthma children admitted and treated in our hospital from April 2017 to April 2018 were selected and randomly divided into two groups with 45 cases in each, the control group were treated with simple budesonide, while the observation group were treated with montelukast and budesonide, and the clinical curative effect, lung function indicators before and after treatment and recurrence rate in three months were compared between the two groups. Results The treatment markedly effective rate and total treatment effective rate in the observation group were obviously higher than those in the control group [71.11%, 95.56% vs 53.33%, 80.00%,the different was statistically significant(χ~2=8.580, 12.121 P<0.05)], after treatment, the FEV1,PEF, FVC levels in the observation group after treatment were(2.26±0.22)L,(3.42±0.63)L/s,(3.96±0.40))L, obviously higher thn those in the control group,the different was statistically significant(t=10.146, 4.589, 10.213, P<0.05); and the recurrent rate in the observation group was obviously lower than that in the control group,the different was statistically significant(2.22% vs11.11%(χ~2=4.234, P<0.05). Conclusion The effect of montelukast and budesonide in treatment of children with asthma is definite, which can obviously improve the lung function and reduce the recurrence rate.
Objective To study the clinical curative effect and recurrent rate of montelukast and budesonide in treatment of children with asthma. Methods 90 cases of asthma children admitted and treated in our hospital from April 2017 to April 2018 were selected and randomly divided into two groups with 45 cases in each, the control group were treated with simple budesonide, while the observation group were treated with montelukast and budesonide, and the clinical curative effect, lung function indicators before and after treatment and recurrence rate in three months were compared between the two groups. Results The treatment markedly effective rate and total treatment effective rate in the observation group were obviously higher than those in the control group [71.11%, 95.56% vs 53.33%, 80.00%,the different was statistically significant(χ~2=8.580, 12.121 P<0.05)], after treatment, the FEV1,PEF, FVC levels in the observation group after treatment were(2.26±0.22)L,(3.42±0.63)L/s,(3.96±0.40))L, obviously higher thn those in the control group,the different was statistically significant(t=10.146, 4.589, 10.213, P<0.05); and the recurrent rate in the observation group was obviously lower than that in the control group,the different was statistically significant(2.22% vs11.11%(χ~2=4.234, P<0.05). Conclusion The effect of montelukast and budesonide in treatment of children with asthma is definite, which can obviously improve the lung function and reduce the recurrence rate.
引文
[1]张亚锋,吕亚洲.布地奈德与孟鲁司特钠联用对哮喘患儿气道功能改善的疗效及其对炎症因子水平的影响[J].抗感染药学,2018,15(6):1096-1098.
[2]郭鹏.布地奈德与孟鲁司特对支气管哮喘患儿临床症状和气道炎症的影响[J].安徽医药,2017,21(10):1861-1864.
[3]阳进,王瀚仪,肖玲,等.孟鲁司特钠联合布地奈德混悬液对哮喘急性发作患儿血清EOS、ECP水平和肺功能的影响[J].现代生物医学进展,2018,18(12):2392-2395.
[4]程秀萍.孟鲁司特联合布地奈德治疗小儿哮喘疗效及其对肺功能的影响[J].全科口腔医学电子杂志,2018,5(17):57.
[5]李春兰,相恒杰.孟鲁司特钠咀嚼片联合布地奈德气雾剂吸入治疗小儿哮喘的疗效与安全性[J].中国医院用药评价与分析,2018,18(4):466-467,470.
[6]黄莉,鲁利群,宁雪梅,等.布地奈德吸入联合孟鲁司特钠对小儿哮喘气道功能及血清炎症因子的影响[J].海南医学院学报,2018,24(1):64-66,70.
[7]白容荣,周九菊,牛建华,等.孟鲁司特钠联合布地奈德对小儿CVA的疗效分析[J].中华肺部疾病杂志:电子版,2018,11(2):219-221.
[8]柴斌英,万俊,包志丹,等.布地奈德雾化剂联合孟鲁司特钠治疗小儿哮喘患儿的疗效及对血清炎性因子的影响[J].河北医药,2018,40(13):1969-1971,1975.
[2]郭鹏.布地奈德与孟鲁司特对支气管哮喘患儿临床症状和气道炎症的影响[J].安徽医药,2017,21(10):1861-1864.
[3]阳进,王瀚仪,肖玲,等.孟鲁司特钠联合布地奈德混悬液对哮喘急性发作患儿血清EOS、ECP水平和肺功能的影响[J].现代生物医学进展,2018,18(12):2392-2395.
[4]程秀萍.孟鲁司特联合布地奈德治疗小儿哮喘疗效及其对肺功能的影响[J].全科口腔医学电子杂志,2018,5(17):57.
[5]李春兰,相恒杰.孟鲁司特钠咀嚼片联合布地奈德气雾剂吸入治疗小儿哮喘的疗效与安全性[J].中国医院用药评价与分析,2018,18(4):466-467,470.
[6]黄莉,鲁利群,宁雪梅,等.布地奈德吸入联合孟鲁司特钠对小儿哮喘气道功能及血清炎症因子的影响[J].海南医学院学报,2018,24(1):64-66,70.
[7]白容荣,周九菊,牛建华,等.孟鲁司特钠联合布地奈德对小儿CVA的疗效分析[J].中华肺部疾病杂志:电子版,2018,11(2):219-221.
[8]柴斌英,万俊,包志丹,等.布地奈德雾化剂联合孟鲁司特钠治疗小儿哮喘患儿的疗效及对血清炎性因子的影响[J].河北医药,2018,40(13):1969-1971,1975.